HCPCS Code J0743: Imipenem-Cilastatin Sodium billing guide

Key takeaways

HCPCS Code J0743 describes injection, cilastatin sodium; imipenem, per 250 mg.

Each billing unit equals 250 mg, so a 500 mg dose is 2 units and a 1,000 mg dose is 4 units.

Most payers require an NDC alongside J0743 on the CMS-1500 or the 837P claim file.

J0742 covers Recarbrio, a different drug that must never be billed as J0743.

Practice management software like Pabau keeps the dose, the units, and the NDC on one record.

HCPCS Code J0743 is the Level II J-code for injection, cilastatin sodium; imipenem, per 250 mg. It covers provider-administered imipenem-cilastatin, sold as Primaxin and as FDA-approved generics. One billing unit equals 250 mg, so a 1,000 mg dose bills as four units.

Imipenem-cilastatin is reserved for serious gram-negative, gram-positive, and polymicrobial infections that narrower agents cannot cover. This reference covers the descriptor, unit calculation, the Medicare payment basis, the NDC crosswalk, documentation requirements, and the errors behind most J0743 denials.

HCPCS Code J0743: official descriptor and code details

HCPCS Code J0743 is a Level II HCPCS code maintained by the Centers for Medicare and Medicaid Services (CMS). It describes a specific drug, route, and quantity that must match the administered dose on every claim.

The semicolon in the official descriptor separates cilastatin sodium from imipenem. The two agents are co-formulated. Cilastatin inhibits the renal enzyme dehydropeptidase-I, which stops the kidney from breaking imipenem down. Both components are present in every vial, and the code covers Primaxin or any FDA-approved generic imipenem-cilastatin product.

Billing units: how to calculate J0743 units

Incorrect unit calculation is the single most common source of J0743 claim errors. Divide the total milligrams administered by 250 to get the number of units to bill. Round to the nearest whole unit under your payer’s rounding policy.

Rounding policy: CMS instructs providers to round to the nearest whole unit. Most payers follow the standard half-unit convention for a dose that falls between exact multiples of 250 mg.

Bill the next full unit up when half a unit or more is used, and the lower unit when less is used. Confirm your MAC’s local policy, because some commercial payers round differently.

Bill only the dose actually administered, not the dose drawn from the vial. If 750 mg is drawn and 50 mg is discarded due to clinical factors, document the amount administered (700 mg) and bill 3 units. Never bill for wasted drug unless your payer explicitly reimburses wastage and your documentation supports it.

J0743 Medicare fee schedule and reimbursement rates

Medicare Part B reimburses provider-administered drugs under the Average Sales Price (ASP) methodology. For HCPCS Code J0743, the payment rate equals ASP + 6% per unit, updated quarterly by CMS. Because ASP changes each quarter, no static dollar figure in this article will remain accurate for long. Always verify the current rate against the quarterly CMS ASP drug pricing files. The Physician Fee Schedule lookup tool carries physician services, not drug ASP pricing, so it is the wrong source for this code.

After a claim processes, the electronic remittance advice (ERA) shows the allowed amount per unit billed. Reconciling that against your expected ASP rate catches underpayments early, before they turn into write-offs.

J0743 fee schedule by payer type

MAC jurisdiction affects whether the claim is covered at all. Different Medicare Administrative Contractors administer Part B claims across US regions. The ASP + 6% formula is national, but a MAC’s local coverage determination can decide whether imipenem-cilastatin is payable for a given indication. Check your own jurisdiction’s policy before the drug is administered.

NDC codes that map to J0743

Most payers require the National Drug Code (NDC) alongside HCPCS Code J0743 on the claim. CMS requires NDC reporting on Part B drug claims submitted on the CMS-1500 and 837P electronic claim file. The NDC identifies the specific product administered: manufacturer, formulation, and package size. Imipenem-cilastatin is available from multiple manufacturers, each carrying a different NDC.

The table below lists representative NDC codes. Verify each one against the current AAPC HCPCS code reference and the CMS NDC-to-HCPCS crosswalk file before submission. Manufacturer NDCs change when a product is reformulated, discontinued, or relabeled.

NDC billing format: CMS requires the 11-digit NDC in a 5-4-2 format on paper claims (CMS-1500, Box 24A). On 837P electronic claims, the NDC goes in Loop 2410. Include the unit of measure qualifier (UN for units, ML for milliliters, GR for grams) and the NDC quantity dispensed. A missing or misformatted NDC is among the most common denial reasons for J-code drug claims.

How to bill J0743: documentation and claim requirements

Every J0743 claim needs documentation that proves medical necessity, confirms the dose administered, and supports the units billed. Payers audit drug claims at higher rates than office visit claims, so a thin record turns into a denial or a post-payment recoupment.

Four decisions sit between the infusion and a payable line item, and each one fixes a different field on the claim.

• Drug order: A signed physician or provider order specifying imipenem-cilastatin, dose in mg, frequency, route, and duration of therapy
• Clinical indication: A documented diagnosis supporting use (e.g., complicated intra-abdominal infection, nosocomial pneumonia, febrile neutropenia) with the corresponding ICD-10-CM code on the claim
• Administration record: Time-stamped nursing or infusion record showing the drug name, lot number, NDC, dose administered in mg, start and stop time, and route
• Units calculated: A visible calculation in the record, such as 1,000 mg administered equals 4 units of J0743. A billing system audit trail showing the derivation also works
• Place of service: Confirmed match between the POS code on the claim and where the infusion actually occurred (office, outpatient infusion center, hospital outpatient department)
• NDC reported: 11-digit NDC in 5-4-2 format with unit of measure and quantity on the CMS-1500 (Box 24A) or 837P Loop 2410

Practice management software like Pabau stores the administration record against the visit it belongs to. The order, the note, and the billed units then sit in one place. Pabau’s claims management software submits the claim from that record and tracks its status. A charge slip carrying the dose in mg, the calculated units, and the NDC makes the handoff to billing almost error-free.

Buy and bill model for J0743

Most outpatient imipenem-cilastatin claims follow the buy-and-bill model. The practice or infusion center purchases the drug from a wholesaler or specialty pharmacy. It then administers the drug and bills the payer for both the drug cost and the administration service.

1. Acquire the drug: Purchase imipenem-cilastatin from a licensed wholesaler. Record the invoice date, NDC, lot number, and acquisition cost. Acquisition cost matters because your net reimbursement (ASP + 6%) must exceed your purchase price for the service to be financially sustainable.
2. Verify patient eligibility: Confirm the patient’s Part B or commercial coverage before administration. Run a real-time eligibility check for formulary status and any prior authorization requirement before the infusion begins.
3. Administer and document: Record dose, route, time, NDC, lot number, and the name of the administering clinician in the patient record. This documentation is what makes the claim payable on first submission.
4. Calculate units and submit: Divide mg administered by 250 and confirm the NDC in 5-4-2 format. On the CMS-1500, J0743 goes in Box 24D and the NDC in Box 24A. On the 837P, they go in Loop 2400 and Loop 2410.
5. Reconcile payment: Compare the ERA payment against the expected ASP + 6% rate. Flag any underpayment for appeal within your payer’s timely filing window.

Medicare and payer coverage for J0743

Medicare Part B covers imipenem-cilastatin when administered incident-to a physician’s service in an office or outpatient infusion setting. Coverage turns on three factors. Those are the clinical indication, the place of service, and whether the drug is reasonable and necessary for the patient’s condition.

• Place of service: Office (POS 11), outpatient infusion center (POS 22), and hospital outpatient department (POS 19) are the most common. Home infusion (POS 12) usually sits under Medicare Part D, not Part B. A waiver-based home infusion benefit is the exception.
• Medical necessity documentation: The record must show why a carbapenem-class antibiotic was required rather than a narrower-spectrum agent. A positive culture result, documented treatment failure with first-line agents, or a patient-specific clinical reason (allergy, multi-drug-resistant organism) all support medical necessity.
• Prior authorization: Medicare Part B generally does not require prior authorization for J-code drugs in office or infusion settings, but Medicare Advantage plans often do. Confirm with the specific plan before administration.
• Medicaid: Coverage is state-specific. Some state Medicaid programs require prior authorization for carbapenems due to antimicrobial stewardship policies. Never assume coverage; verify with the state Medicaid fee schedule and any applicable Drug Use Review requirements.

Effective dates and code status for HCPCS Code J0743

HCPCS Code J0743 has been active and valid for billing purposes across recent code years. The table below reflects available information as of the date of publication. Always verify current status against the CMS HCPCS Level II alpha-numeric code file for the applicable benefit year before submitting claims.

Related HCPCS codes for antibiotic injections

Imipenem-cilastatin is one of several carbapenem and broad-spectrum antibiotic J-codes. The code most often confused with J0743 is J0742, which covers a different three-drug product. The table below lists the codes most likely to appear alongside J0743 on a claim.

J0743 vs. J0742: This is the comparison that matters most. Recarbrio (imipenem-cilastatin-relebactam) is a newer product approved for carbapenem-resistant organisms, and it bills under J0742. The two drugs share the imipenem-cilastatin backbone but differ by the addition of relebactam.

J0741 is not part of that pair. It covers cabotegravir and rilpivirine, an injectable HIV therapy with no relationship to either carbapenem. Billing J0743 for Recarbrio, or the reverse, is a coding error regardless of clinical intent.

The NDC on the vial settles which of the two codes applies, so check the label rather than the order. The full HCPCS code library covers drug and supply codes outside the antibiotic range.

Common billing errors and how to avoid them

Six mistakes account for most J0743 denials and audit findings. Each one is cheap to prevent at the point of documentation and expensive to unwind after the claim has been paid.

Practices with a disciplined denial process review J-code denials weekly rather than monthly. A weekly sweep catches unit errors, missing NDCs, and POS mismatches while the claim is still inside the appeal window.

A log of denial reasons by code also reveals patterns. One payer may reject J0743 without an authorization number every time, and that stays invisible until the revenue loss is large.

Audit a sample of J0743 claims internally each quarter. Three checks cover most of the exposure.

• Compare the dose in the administration record against the units billed
• Confirm the NDC on the claim matches the product actually administered
• Verify the POS code against where the infusion took place

Medicare RAC and commercial auditors run the same exercise. Running it first removes the common vulnerabilities before they attract outside scrutiny.

How Pabau keeps J0743 units tied to a documented dose

In most practices the dose lives in the infusion record and the NDC lives on a vial label in the treatment room. The unit count is then typed into the billing system from whatever the biller can find. Every handoff between those three is a chance to lose a digit.

Pabau holds the administration record, the invoice, and the claim against the same appointment. The clinician documents the dose once, and the billing team works from that record instead of re-entering it. Claims go out through the built-in clearinghouse connection, and their status comes back onto the same visit.

That shortens the audit trail. When a payer asks why four units of J0743 were billed, the answer is a lookup rather than a search through paper infusion logs.

Keep every J0743 unit tied to a documented dose

Pabau stores the infusion record, the invoice, and the claim against the same appointment. Your billing team works from the dose that was documented, rather than re-entering it.

Book a demo

Conclusion

J0743 is not a difficult code to bill. The denials come from four small facts that live in four different places. Those are the dose given, the divisor of 250, the NDC on the label, and the field the claim format expects.

Practices that capture those four at the point of care rarely appeal a J0743 claim. Practices that reconstruct them at billing time appeal often, and win late. The accuracy is decided in the treatment room, not in the billing queue.

One quarterly habit is worth keeping. Pull ten J0743 claims and trace each billed unit back to a documented milligram. Book a demo to see how Pabau links the infusion record to the claim so that trace takes minutes.

Continue your research

Need to understand the broader billing submission process? What is medical billing covers the end-to-end revenue cycle from charge capture to payment posting.

Want to reduce claim denials across your practice? Denial management in healthcare explains how to build a systematic appeals and prevention workflow.

Looking to verify coverage before you administer? Insurance eligibility verification walks through real-time benefit checks for drug coverage and prior authorization.

Frequently asked questions